@article{10655, keywords = {*Cardiovascular Diseases/epidemiology/prevention & control, *Diabetes Mellitus, Type 2/complications/drug therapy, *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Glucose, *Heart Failure/epidemiology, Hospitalization, Humans, *Myocardial Infarction, Primary health care, *Renal Insufficiency, Chronic/complications/epidemiology, Retrospective Studies, Sodium, *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use, *Symporters, United Kingdom/epidemiology, Cardiovascular disease, clinical trial, dapagliflozin, diabetes complications, dipeptidyl peptidase-4 inhibitor, heart failure}, author = {I. Idris and R. Zhang and J. Mamza and M. Ford and T. Morris and A. Banerjee and K. Khunti}, title = {Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease}, year = {2021}, journal = {Diabetes Obes Metab}, volume = {23}, edition = {2021/05/12}, number = {10}, pages = {2207-2214}, isbn = {1462-8902 (Print)1462-8902}, doi = {10.1111/dom.14437}, note = {1463-1326 Idris, Iskandar Zhang, Ruiqi Mamza, Jil Billy Ford, Mike Morris, Tamsin Banerjee, Amitava Khunti, Kamlesh Orcid: 0000-0003-2343-7099 DH_/Department of Health/United Kingdom Journal Article Research Support, Non-U.S. Gov't Diabetes Obes Metab. 2021 Oct;23(10):2207-2214. doi: 10.1111/dom.14437. Epub 2021 Aug 2.}, language = {eng}, }